NCT00088647
Terminated
Phase 1
A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors
Wyeth is now a wholly owned subsidiary of Pfizer0 sitesAugust 2, 2004
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Primary Endpoint
- To evaluate the safety, tolerability and MTD of IV MST-997 throughout patients participation on trial.
- Status
- Terminated
- Last Updated
- 19 years ago
Overview
Brief Summary
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Documented histological or cytological diagnosis confirming the presence of malignant solid tumor
- •Tumor progression after conventional therapy for cancer or a malignant solid tumor for which no conventional therapy exists
- •Subjects enrolled in the MTD confirmation cohort should have a documented histologic and/or cytologic diagnosis of metastatic breast cancer or non-small cell lung cancer (NSCLC) and should not have received more than 2 prior chemotherapy regimens for metastatic disease (adjuvant and neoadjuvant chemotherapy will not be included in the maximum of 2 prior regimens described above)
Exclusion Criteria
- •Subjects with symptomatic or clinically active central nervous system (CNS) metastases. Subjects who have had prior treatment with radiotherapy or surgical resection for CNS metastases will be permitted if CNS metastases have remained stable and have not required any treatment for at least 3 months prior to first dose of test article
- •History of any other primary malignancy with less than 5 years documentation of a disease-free state (Subjects with a history of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ, which have been successfully treated, are not excluded)
- •Recent major surgery (within 14 days before the first dose) or chemotherapy within 28 days before the first dose of MST-997 (42 days if the previous chemotherapy included nitrosoureas or mitomycin C)
Outcomes
Primary Outcomes
To evaluate the safety, tolerability and MTD of IV MST-997 throughout patients participation on trial.
Secondary Outcomes
- To obtain preliminary information on the pharmacokinetics (during cycle 1) and antitumor activity of MST-997 (approximately every 8 weeks).
Similar Trials
Completed
Phase 1
S 81694 Plus Paclitaxel in Metastatic Breast CancerMetastatic Breast CancerMetastatic Triple Negative Breast CancerNCT03411161Institut de Recherches Internationales Servier22
Completed
Phase 1
Safety Trial Of CTX Cells In Patients With Lower Limb IschaemiaPeripheral Arterial DiseaseNCT01916369ReNeuron Limited5
Completed
Phase 1
Safety Study of Gene Therapy in Treating Critical Leg IschemiaCritical Limb IschemiaNCT00696124Helixmith Co., Ltd.12
Unknown
Phase 1
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02211443Sinocelltech Ltd.21
Completed
Phase 1
Dose-Finding Study of PDC31 in Patients With Primary DysmenorrheaDysmenorrheaNCT01250587PDC Biotech GmbH24